Cancer Epidemiology

Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Cancer Epidemiology, Biomarkers & Prevention Research Article Reproductive Factors and Exogenous Hormone Use in Relation to Risk of Glioma and Meningioma in a Large European Cohort Study Dominique S. Michaud1,2, Valentina Gallo1, Brigitte Schlehofer3, Anne Tjønneland7, Anja Olsen7, Kim Overvad5, Christina C. Dahm5,6, Rudolf Kaaks4, Annekatrin Lukanova4, Heiner Boeing8, Madlen Schütze8, Antonia Trichopoulou9,11, Christina Bamia9, Andreas Kyrozis11,10, Carlotta Sacerdote12, Claudia Agnoli13, Domenico Palli14, Rosario Tumino15, Amalia Mattiello16, H. Bas Bueno-de-Mesquita17, Martine M. Ros17,18, Petra H. M. Peeters19, Carla H. van Gils19, Eiliv Lund20, Kjersti Bakken20, Inger T. Gram20, Aurelio Barricarte21,22, Carmen Navarro22,23, Miren Dorronsoro26, Maria José Sánchez22,24, Laudina Rodríguez25, Eric J. Duell27, Göran Hallmans28, Beatrice S. Melin29, Jonas Manjer30, Signe Borgquist31, Kay-Tee Khaw33, Nick Wareham34, Naomi E. Allen32, Konstantinos K. Tsilidis32, Isabelle Romieu35, Sabina Rinaldi35, Paolo Vineis1, and Elio Riboli1 Abstract Background: The etiologies of glioma and meningioma tumors are largely unknown. Although reproductive hormones are thought to influence the risk of these tumors, epidemiologic data are not supportive of this hypothesis; however, few cohort studies have published on this topic. We examined the relation between reproductive factors and the risk of glioma and meningioma among women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Methods: After a mean of 8.4 years of follow-up, 193 glioma and 194 meningioma cases were identified among 276,212 women. Information on reproductive factors and hormone use was collected at baseline. Cox proportional hazard regression was used to determine hazard ratios (HR) and 95% confidence intervals (95% CI). Results: No associations were observed between glioma or meningioma risk and reproductive factors, including age at menarche, parity, age at first birth, menopausal status, and age at menopause. A higher risk of meningioma was observed among postmenopausal women who were current users of hormone replacement therapy (HR, 1.79; 95% CI, 1.18-2.71) compared with never users. Similarly, current users of oral contraceptives were at higher risk of meningioma than never users (HR, 3.61; 95% CI, 1.75-7.46). Conclusion: Our results do not support a role for estrogens and glioma risk. Use of exogenous hormones, especially current use, seems to increase meningioma risk. However, these findings could be due to diagnostic bias and require confirmation. Impact: Elucidating the role of hormones in brain tumor development has important implications and needs to be further examined using biological measurements. Cancer Epidemiol Biomarkers Prev; 19(10); 2562–9. ©2010 AACR. Authors' Affiliations: 1Department of Epidemiology and Public Health, Imperial College, London, United Kingdom; 2 Brown University, Providence, Rhode Island; 3 Unit of Environmental Epidemiology and 4 Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 5Department of Epidemiology, School of Public Health, Aarhus University, and 6 Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark; 7Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark; 8 Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany; 9WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, and 101st Department of Neurology, Eginition Hospital, University of Athens Medical School, and 11Hellenic Health Foundation, Athens, Greece; 12 Department of Biomedical Science and Human Oncology, CPO-Piemonte, Torino, Italy; 13Nutritional Epidemiology Unit, Department of Preventive & Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; 14Molecular and Nutritional Epidemiology Unit, ISPO-Cancer Research and Prevention Institute, Florence Italy; 15Cancer Registry and Histopathology Unit, “Civile-M.P. Arezzo” Hospital, ASP 7 Ragusa, Italy; 16Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy; 17National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands; 18 Department of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; 19Julius Center for Health Sciences and Primary Care, University Medical 2562 Center Utrecht, Utrecht, the Netherlands; 20Department of Community Medicine, University of Tromsø, Tromsø, Norway; 21Public Health Institute of Navarra, Pamplona, Spain; 22CIBER Epidemiología y Salud Pública (CIBERESP), Spain; 23Department of Epidemiology, Regional Health Authority, Murcia, Spain; 24Andalusian School of Public Health, Granada, Spain; 25Public Health and Participation Directorate, Health and Health Care Services Council, Asturias, Spain; 26 Public Health Division of Gipuzkoa, Basque Regional Health Department and CIBERESP, Spain; 27 Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology, Barcelona, Spain; 28Department of Public Health and Clinical Medicine, Nutritional Research, Umeå University, and 29Department of Radiation Sciences, Oncology, Umeå University hospital, Umeå, Sweden; Departments of 30Plastic Surgery and 31Oncology, Skåne University Hospital Malmö, Lund University, Malmö, Sweden; 32 Cancer Epidemiology Unit, University of Oxford, Nuffield Department of Clinical Medicine, Oxford, United Kingdom; 33Department of Public Health and Primary Care, University of Cambridge, and 34MRC Epidemiology Unit, Cambridge, United Kingdom; and 35International Agency for Research on Cancer (IARC), Lyon, France Corresponding Author: Dominique S. Michaud, Brown University, Box G-S121-2, Providence, RI 02912. Phone: 401-863-6365. E-mail: Dominique_Michaud@brown.edu doi: 10.1158/1055-9965.EPI-10-0447 ©2010 American Association for Cancer Research. Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Reproductive Factors, Hormone Use, and Brain Tumors Introduction The etiologies of meningiomas and gliomas, the two most common types of brain tumors, remain largely unknown as established risk factors for many cancers, such as smoking, alcohol, and occupational exposures, do not seem to play a role in these tumors. Established risk factors, including ionizing radiation, family history, certain rare genetic conditions, and a few chromosomal regions (1, 2), can only explain a small portion of total brain tumor cases, leaving the majority of cases with unknown causes. Sex differences in glioma and meningioma incidence suggest that hormones could influence the development of these tumors; the incidence of meningiomas is about 2 times greater in women than in men, whereas the incidence of gliomas is around 1.5 times greater in men than in women (3). Increased growth rates of meningiomas have been observed during pregnancy (4), and a strong association exists between breast cancer and meningioma (5). Taken together, these observations support a role for female hormones in the etiology of meningiomas. Reproductive factors, including age at menarche, age at first birth, number of pregnancies, and menopausal status, have been examined in relation to meningioma and/or glioma in several case-control studies (6-16) and in three cohort studies (17-20). The majority of findings from these studies are null or inconsistent with respect to direction of association. For meningioma, four studies reported elevated risks with hormone replacement therapy (HRT) use (7, 19, 21, 22). Findings in relation to oral contraceptive use have been mostly null for both glioma and meningioma risk (7, 9-11, 14, 18, 20). Given that most previous studies on hormonal factors and brain tumors have been case-control studies, and findings are inconsistent, we examined reproductive and exogenous hormone use in relation to risk of glioma and meningioma in a large multicentered prospective cohort study. Materials and Methods Study cohort The European Prospective Investigation into Cancer and Nutrition (EPIC) prospective cohort study was initiated in the early 1990s when 23 centers in 10 European countries collaboratively recruited more than half a million individuals. Additional details on the EPIC study design are reported elsewhere (23). Loss to follow-up (defined as unknown vital status at the last follow-up time) was <6% across centers. Approval for the study was obtained from the ethical review boards of the participating institutions and from the International Agency for Research on Cancer. Case ascertainment Incident cancer cases (including benign brain tumors) were identified through linkage to population cancer www.aacrjournals.org registries in Denmark, Italy, the Netherlands, Norway, Spain, Sweden, and the United Kingdom, or with a combination of methods including linkage to health insurance records, cancer and pathology registries, and active follow-up of study participants or their next of kin in France, Germany, and Greece. We removed France from this analysis due to missing histology on cancer cases. We included all primary incident cases diagnosed with glioma [coded using International Classification of Diseases-Oncology (ICD-O) 2nd edition: 9380-9460, 9505] or meningioma (ICD-O-2 codes 9530-9537) through the end of follow-up (from January 2003 to November 2006 depending on center). Among all women, a total of 193 glioma and 194 meningioma cases were available for analyses on reproductive factors and oral contraceptive use, and 159 glioma and 150 meningioma cases were available for the HRT analyses among perimenopausal and postmenopausal women. Assessment of HRT, oral contraceptives, and reproductive factors Information on HRT use, oral contraceptive use, and reproductive factors were collected on the baseline questionnaires. Participants were asked about ever and current use of HRT, age at start and total duration of use, route of administration, and brand name of current HRT use. Analyses were done for ever, current, and former use of HRT, and duration of ever HRT use. Because few cases at baseline were current HRT users (50 meningioma and 34 glioma) we had insufficient power to examine type of HRT. Information on ever use of oral contraceptives, duration of use, and ages at starting and stopping use was collected. Age at menarche and menopause, number of full-term pregnancies (live and still births), age at the first full-term pregnancy, and the reason for menopause (natural versus surgical) were self-reported at recruitment. Information on breastfeeding and its cumulative duration was collected for the first three full-term pregnancies and the last one. Statistical analysis We excluded prevalent cancers and benign brain tumors at recruitment (except for nonmelanoma skin cancer) and individuals with incomplete follow-up for this analysis (n = 27,082). Only women were included in this analysis. After excluding data from France (missing histologic data on cancer cases), 276,451 women were available for the main analysis. Menopausal status was defined according to information on menstruation status, ovariectomy, and hysterectomy (for details please refer to Allen et al.; ref. 24). Women were considered perimenopausal if they reported no regular menses over the past 12 months (<9 cycles). Women with missing or incomplete information on the cycle of menses, who reported a hysterectomy, or who indicated use of exogenous hormones while still Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. 2563 Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Michaud et al. menstruating were considered postmenopausal if they were ≥55 years old, perimenopausal if they were between 46 and 55 years, or premenopausal if they were <46 years old at recruitment. For the HRT analyses, we combined perimenopausal women with postmenopausal women because the risk of brain tumors was similar for perimenopausal and postmenopausal women (compared with premenopausal women). Hazard ratios (HR) and their 95% confidence intervals (95% CI) for brain tumors were estimated using Cox proportional hazards models with age at enrolment as the time scale. Person-time was calculated from date of recruitment until date of incident brain tumor diagnosis, death, date of last contact, or end of follow-up period, whichever came first. All models were stratified by EPIC participating center, to account for center effects related to different recruitment and follow-up procedures, and by age at recruitment in 1-year categories. The proportionality of hazards was verified based on the slope of the Schoenfeld residuals over time, which is equivalent to testing that the log hazard ratio function is constant over time. All models were adjusted (using categorical variables) for smoking status (never, former, current), education (none/primary, technical/professional, secondary, university), and body mass index (BMI; <25, ≥25-<30, ≥30 kg/m 2); although these covariates did not appreciably alter the associations, we kept them in the model as these have been previously associated with the risk of brain tumors in one or more studies. Other covariates often adjusted for in cancer analyses were not included in the multivariate models as they are not known or suspected risk factors for brain tumors. Country-specific analyses were also done. All P values were two-sided. All analyses were done using SAS 9.1 (SAS Institute Inc.). Results After an average of 8.4 years of follow-up, 194 cases of meningioma and 193 cases of glioma were diagnosed among women from nine countries in the EPIC cohort. The average age (SD) at recruitment was 50.4 (10.5) years. The average age (SD) at diagnosis was 53.9 (8.0) years for meningioma and 54.1 (8.9) years for glioma. Table 1 shows the distribution of exogenous hormone use by country. Oral contraceptive (OC) use was highest in Germany (80.8%) and the Netherlands (72.7%) and lowest in Greece (9.6%). Among postmenopausal and perimenopausal women, HRT use was highest in Germany (55.4%) and lowest in Greece (6.8%). We examined the relation between potential risk factors (i.e., age, BMI, education, and smoking) and HRT use (Table 2). Women who were current users of HRT at recruitment were younger, slightly leaner, more educated, and more likely to be current smokers than women who were past or never HRT users. In addition, women on HRT were also more likely to have been ever users 2564 Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 of OCs (65% of current HRT users versus 41% of never HRT users). There was a suggestive increased risk of glioma among postmenopausal and perimenopausal women, compared with premenopausal women, but these associations were not statistically significant (Table 3); the association remained statistically insignificant when perimenopausal and postmenopausal women were combined (HR, 1.68; 95% CI, 0.82-3.41). In contrast, menopausal status seemed to be inversely related to the risk of meningioma (Table 3; combining perimenopausal and postmenopausal, HR, 0.63; 95% CI, 0.34-1.17, compared with premenopausal women). Compared with premenopausal women, women who had a bilateral ovariectomy had a statistically significant elevated risk of glioma (HR, 3.51; 95% CI, 1.45-8.49), and possibly meningioma (as the association was not statistically significant, HR, 1.89; 95% CI, 0.84-4.26; Table 3); these associations did not change when controlling for OC or HRT use. Other reproductive factors, including age at menarche, age at menopause, parity, and age at first birth, were not associated with risk of meningioma or glioma (Table 3). Being ever parous compared with nulliparous was not associated with risk of glioma (HR, 0.96; 95% CI, 0.88-1.04) or meningioma (HR, 1.00; 95% CI, 0.93-1.08). Women who had a hysterectomy (after excluding women who had a bilateral ovariectomy) were at slightly higher risk of meningioma (Table 3). Women with one ovary removed did not have a higher risk of glioma or meningioma (data not shown). Likewise, breastfeeding (ever or by duration) was not related to either type of brain tumors (data not shown). Women who reported being current users of OCs at the time of recruitment into the cohort had a substantially higher risk of meningioma than women who never used OCs (HR, 3.61; 95% CI, 1.75-7.46), whereas former users did not have an elevated risk (Table 3). This association was very similar among premenopausal women (HR, 3.70; 95% CI, 0.88-15.6; total 40 cases, 3 cases current OC users) and postmenopausal women mutually adjusting for HRT use (HR, 3.54; 95% CI, 1.50-8.37, total 149 cases, 7 cases current OC users; note that current OC users were in the perimenopausal group). There was no clear dose-response with duration of ever OC use and meningioma risk overall (Table 3), but there was a dose-response among premenopausal women [compared with never, HR (95% CI) of 1.21 (0.36-4.06), 1.55 (0.534.56), 2.97 (1.08-8.15), 3.22 (1.04-10.0), and 3.60 (1.0013.0) for ≤1, >1-<5, ≥5-<10, ≥10-≤15, and >15 years of use, respectively, P trend = 0.01; data not in tables). No association with OC use was observed in relation to glioma risk (Table 3). Among postmenopausal and perimenopausal women, current users of HRT had a higher risk of meningioma (HR, 1.79; 95% CI, 1.19-2.71) compared with never users, and the risk was also elevated (though not significantly so) among past HRT users (Table 4). There was no clear dose-response relationship between duration of HRT use Cancer Epidemiology, Biomarkers & Prevention Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. www.aacrjournals.org Characteristic OC ever use (%) Yes No Unknown Nulliparous (%) Mean age at first pregnancy (SD), y* Mean age at menarche (SD), y Hysterectomy (%) Among all postmenopausal or perimenopausal women Status of use Current Past Unknown 194 193 28 41 15 12 18 18 16 24 43 12 16 15 23 43 4 4 31 24 55.9 40.6 3.5 12.8 24.8 (4.4) 57.6 41.3 1.1 8.8 23.7 (4.2) 80.8 19.0 0.2 11.2 24.3 (4.4) 40.4 58.1 1.5 10.2 25.8 (4.3) 72.7 26.7 0.6 19.8 25.4 (4.2) 64.1 35.9 0 8.5 24.1 (4.5) 42.1 57.8 0.1 9.6 24.6 (3.9) 64.9 31.9 3.2 27.6 25.9 (4.7) 9.6 89.8 0.6 6.8 24.2 (4.7) 38.8 36.6 24.7 7.4 24.7 (4.5) 13.1 (1.6) 13.6 (1.6) 13.2 (1.5) 12.5 (1.5) 13.3 (1.6) 13.3 (1.4) 12.9 (1.6) 12.9 (1.6) 13.2 (1.7) 13.5 (1.5) 10.2 n = 174,134 14.8 n = 27,209 15.0 n = 15,267 8.9 n = 19,135 17.4 n = 18,157 4.7 n = 23,311 8.4 n = 11,772 12.5 n = 28,977 8.2 n = 9,736 — n = 20,570 48.7 (4.8) 49.0 (4.9) 49.5 (3.3) 49.0 (4.3) 48.5 (5.1) 47.7 (4.0) 48.0 (4.7) 48.3 (5.5) 47.9 (5.2) 49.2 (4.6) 34.2 58.3 7.4 n = 62,092 46.7 51.4 1.9 n = 12,709 55.4 36.3 8.3 n = 8,455 23.9 74.3 1.8 n = 4,583 26.1 72.6 1.3 n = 4,739 45.3 54.7 0 n = 10,562 18.7 80.1 1.2 n = 2,195 38.3 56.9 4.9 n = 11,087 6.8 92.7 0.5 n = 662 22.5 33.9 43.6 n = 4,637 66.6 29.1 4.3 65.5 34.4 0.03 77.9 22.1 0 44.8 54.4 0.8 51.5 44.6 3.9 79.8 8.0 12.2 55.2 43.8 1.0 67.8 30.6 1.6 32.5 67.4 0.1 63.2 18.5 18.3 *Among parous women. † Among natural postmenopausal women. Reproductive Factors, Hormone Use, and Brain Tumors Mean age at menopause (SD), y† HRT ever use (%) Yes No Unknown Among ever HRT users All Denmark Germany Italy Netherlands Norway Spain United Kingdom Greece Sweden (n = 276,451) (n = 29,320) (n = 28,481) (n = 31,519) (n = 27,168) (n = 35,941) (n = 25,356) (n = 56,357) (n = 15,396) (n = 26,913) Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Meningioma cases Glioma cases Among all women Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. Table 1. Use of oral contraceptive at recruitment among all women and menopausal hormone therapy among perimenopausal and postmenopausal women in the EPIC cohort by country 2565 Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Michaud et al. Table 2. Distribution of baseline characteristics by menopausal hormone therapy use among perimenopausal and postmenopausal women and by oral contraceptive use among all women in the EPIC cohort Characteristic Mean age at recruitment (SD), y Smoking status (%) Never Former Current Mean BMI (SD), kg/m2 Ever use of OCs (%) Yes No Unknown Education (%) None/Primary Technical/Professional Secondary University Mean age at menarche (SD), y Nulliparous (%) Mean age at first pregnancy (SD), y* Mean age at menopause (SD), y† Hysterectomy (%) Menopausal hormone therapy use Oral contraceptive use Never (n = 101,573) Former (n = 17,362) Current (n = 39,711) Never (n = 112,303) Former (n = 136,862) Current (n = 16.223) 57.0 (7.4) 57.4 (5.8) 54.4 (5.3) 54.8 (9.9) 48.7 (8.8) 37.2 (9.2) 59.0 21.7 19.3 26.5 (4.8) 50.7 26.4 22.9 26.3 (4.4) 47.7 28.0 24.3 25.1 (3.9) 62.8 18.8 18.5 26.5 (4.8) 46.7 27.8 25.5 24.9 (4.3) 54.1 23.1 22.8 23.6 (3.8) 41.0 58.2 0.8 53.2 46.1 0.7 64.6 34.6 0.8 48.8 24.2 14.4 12.6 13.3 (1.6) 9.3 25.0 (4.4) 48.7 (4.8) 12.7 43.0 30.5 13.1 13.4 13.2 (1.6) 9.7 24.5 (4.3) 48.2 (5.3) 19.2 33.0 36.0 14.7 16.3 13.3 (1.6) 7.9 24.2 (4.2) 47.5 (5.5) 23.1 52.7 20.9 13.6 12.8 13.2 (1.6) 13.1 25.0 (4.4) 48.5 (5.1) 13.7 27.4 32.0 18.0 22.6 13.1 (1.5) 10.4 24.7 (4.5) 48.4 (4.8) 11.8 12.7 32.5 23.0 31.8 12.9 (1.5) 37.4 24.8 (4.5) 44.8 (7.7) 0 NOTE: Values derived by χ2 and one-way ANOVA or Kruskal-Wallis test; all tests were P < 0.001. *Among parous women. † Among natural postmenopausal women. and meningioma risk, and no association with HRT use and risk of glioma (Table 4). Discussion In this large European prospective cohort study, we observed elevated risks of meningioma among users of OCs or HRT at enrolment when compared with never users. No associations were found for reproductive factors and risk of meningioma. For glioma, we observed no associations with reproductive factors or exogenous hormone use. However, a significantly elevated risk of glioma was observed among women who had undergone a bilateral ovariectomy at baseline, and a statistically nonsignificant elevated risk was also noted for meningioma tumors; the positive associations were not explained by HRT use. Although the findings for women with bilateral ovariectomy were unexpected and should be interpreted with caution, more studies should examine these to determine if they are of potential significance. Supporting evidence for a role of hormones in brain tumors comes from a number of case reports of women who experienced rapid changes in symptoms during 2566 Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 pregnancy that were related to the presence of a meningioma (either resulting in a diagnosis or a recurrence of symptoms from an existing tumor; refs. 25-27). Similarly, a study reported growth of a meningioma after estrogenprogestin therapy in a transsexual patient (28). Biological data support an association as well; in vitro studies have shown proliferation of meningioma cells with exposure to estradiol or progesterone (29), and inhibition of glioma cell growth with estrogen (30, 31). To date, studies that have examined reproductive hormones and brain tumors have been largely based on case-control studies. Some of these had small case numbers or relied on proxy-interviews for a portion of the data collected for deceased cases (up to 83% of all cases; ref. 12); moreover, given the low incidence rate of brain tumors, identifying the true source population and representative controls is challenging, and consequently, in these studies, bias is difficult to rule out. Therefore, cohort studies can provide more reliable evidence. Overall, positive associations between age at menarche and glioma risk have been observed in five studies (four case-control and one cohort; refs. 9, 10, 14, 16, 18), which suggests that delayed puberty may increase subsequent Cancer Epidemiology, Biomarkers & Prevention Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Reproductive Factors, Hormone Use, and Brain Tumors risk of glioma. In contrast, associations between age at menarche and meningioma have been largely null (6, 8, 10, 11), with one exception where a positive association was reported in a cohort study (19). Other reproductive factors that could influence lifetime hormonal exposure, such as age at menopause and age at first birth, have not been associated with risk of glioma or meningioma. Our observation for meningioma risk and HRT was consistent with two prospective cohort studies: the Nurses' Health Study (current versus never users, relative Table 3. Reproductive factors and risk of meningioma and glioma in the EPIC cohort No. of subjects Menopausal status Premenopausal 102,232 Natural postmenopausal 118,587 Perimenopausal 47,170 Bilateral oopherectomy 8,029 Hysterectomy† No 209,754 Yes 20,883 Missing 37,352 Age at menopause (years)‡ <47 25,243 47-53 52,394 >53 17,888 Missing 70,232 Parity 0 35,341 1 31,409 2 81,492 ≥3 104,215 Missing 23,561 Age at first full-term pregnancy (years) Nulliparous 35,341 <25 115,707 ≥25-≤30 79,538 >30 21,871 Missing 23,561 Age at menarche (years) <12 50,216 ≥12-≤15 207,822 >15 17,980 OC use Never 112,105 Former 136,672 Current 16,201 Missing 11,040 Duration of ever OC use (years) Never 112,105 ≤1 29,804 >1-<5 34,657 ≥5-<10 34,451 ≥10-≤15 27,742 >15 21,277 Missing 15,982 Meningioma Meningioma HR (95% CI)* Glioma Glioma HR (95% CI)* 44 99 38 13 1.0 0.69 (0.35-1.36) 0.57 (0.30-1.11) 1.89 (0.84-4.26) 34 108 37 14 1.0 1.62 (0.75-3.47) 1.69 (0.81-3.54) 3.51 (1.45-8.49) 112 21 48 1.0 1.32 (0.81-2.17) 127 20 32 1.0 1.16 (0.71-1.91) 26 41 13 57 1.0 0.75 (0.45-1.24) 0.75 (0.38-1.49) 25 44 20 56 1.0 0.81 (0.49-1.33) 1.08 (0.59-1.97) 12 19 59 87 17 1.0 0.97 (0.47-2.02) 1.07 (0.57-2.04) 1.40 (0.75-2.59) 18 21 70 73 11 1.0 1.29 (0.67-2.48) 1.58 (0.91-2.76) 1.18 (0.68-2.06) 12 96 57 12 17 1.0 1.28 (0.69-2.39) 1.18 (0.62-2.22) 0.99 (0.44-2.23) 18 94 54 16 11 1.0 1.49 (0.86-2.58) 1.16 (0.66-2.04) 1.42 (0.71-2.84) 36 140 18 1.00 0.80 (0.54-1.17) 1.01 (0.55-1.84) 36 142 15 1.0 0.87 (0.60-1.28) 0.88 (0.47-1.63) 81 92 10 11 1.0 1.20 (0.86-1.68) 3.61 (1.75-7.46) 90 84 8 11 1.0 0.84 (0.61-1.18) 1.23 (0.53-2.83) 1.0 (0.66-1.83) (0.73-1.95) (1.05-2.65) (0.55-1.87) (0.86-2.77) 90 16 17 22 18 13 17 81 20 23 28 14 15 13 1.10 1.19 1.66 1.01 1.54 0.73 0.76 1.00 0.92 0.79 1.0 (0.42-1.28) (0.44-1.30) (0.61-1.65) (0.53-1.59) (0.43-1.47) *Multivariate model includes smoking status, education, BMI, and menopausal status. † Removing women with bilateral ovariectomy. ‡ Among postmenopausal women (those missing are mostly perimenopausal). www.aacrjournals.org Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. 2567 Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Michaud et al. Table 4. Hormone replacement therapy in relation to risk of meningioma and glioma among perimenopausal and postmenopausal women in the EPIC cohort No. of subjects HRT use Never 101,394 Former 17,324 Current 39,617 Missing 15,451 Duration of ever HRT use (years) Never and ≤1 118,360 >1-≤3 12,918 >3-≤5 8,499 >5-≤10 9,678 >10 4,239 Missing 20,092 Meningioma Meningioma MV HR (95% CI)* Glioma Glioma MV HR (95% CI)* 67 15 50 18 1.0 1.40 (0.78-2.49) 1.79 (1.18-2.71) 91 18 34 16 1.00 0.93 (0.55-1.56) 0.76 (0.49-1.19) 1.0 (0.62-2.25) (1.28-4.20) (0.51-2.32) (0.55-3.30) 106 12 8 5 6 22 83 11 14 8 6 28 1.18 2.32 1.09 1.34 0.91 0.93 0.36 0.89 1.00 (0.49-1.68) (0.44-1.94) (0.13-0.98) (0.37-2.14) Abbreviation: MV, multivariate. *Adjusting for smoking status, education, surgical/natural/perimenopause, oral contraceptive use, and BMI. risk (RR), 1.86; 95% CI, 1.07-3.24; 66 meningioma postmenopausal cases; ref. 19) and the Million Women Study (current versus never, RR, 1.34; 95% CI, 1.03-1.75; ref. 22), and with two retrospective studies (comparing ever to never HRT use, OR, 1.7; 95% CI, 1.0-2.8; ref. 7; and OR, 2.2; 95% CI, 1.9-2.6; ref. 21). However, three other casecontrol studies found no associations with HRT and meningioma (6, 10, 11). The association among former users was not as strong in our dataset (Table 4), suggesting that the effect, if causal, is likely to act late in the stages of carcinogenesis. However, it is unclear how hormones are involved in brain tumors from a mechanistic standpoint. Results from earlier studies on oral contraceptive use and risk of meningiomas are less consistent with our findings, as most of the earlier studies reported null associations (7, 10, 19, 20) and one association was inverse (6). However, few of the previous studies reported results for current use of OC; one case-control with data on current use observed a RR of 2.5 (95% CI, 0.5-12.6; ref. 11), whereas two other reported small increased risk with large confidence intervals due to small case numbers for current OC use (RR, 1.34; 95% CI, 0.18-9.96; ref. 19; and RR, 1.33; 95% CI, 0.43-4.12; ref. 10). Therefore, it is possible that an association was missed in some studies if most users were past users and if the effect is only present among current users (as observed with HRT use). It is conceivable that the mechanism involves increased tumor growth rates during the exposure period (current use) and that the risk decreases with time after no longer being a current user. The statistically significant doseresponse relationship for duration of OC use (among ever users) observed among premenopausal women (at baseline) supports this hypothesis; more research is needed to examine this finding. Alternatively, the increase in risk of meningioma among active exogenous hormone users could be due 2568 Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 to diagnostic bias; conceivably, women under prescription drugs who are under more rigorous or more frequent medical surveillance may be more likely to have a follow-up of symptoms that could lead to the diagnosis of benign meningioma. In this cohort, age-specific rates were comparable with those in the United States (which are comparable with European rates; ref. 32). In this cohort, the age-specific rates for glioma were 4.2 (per 100,000) for ages 35 to 44 and 11.5 for ages 65 to 74, and 2.9 and 11.5 for meningiomas in those same age groups, respectively. In the Central Brain Tumor Registry of the United States report (which separates benign and malignant tumors), the age-specific rates range from 4.4 at ages 35 to 44, to 17.3 for ages 65 to 74 for glioma, and from 2.9 to 14.2 for the same age comparisons for meningioma. Therefore, case ascertainment seems to be as expected in this cohort for both subtypes of brain tumors. The strengths of this cohort study include a prospective design, which removes potential error from selection bias or use of proxy interviews, and detailed data on reproductive factors, exogenous hormone use, and other variables that could be potential confounders. The weaknesses of this study include having no followed data on HRT use, and the change in HRT, OC, and/or menopausal status among some women during follow-up, which will cause misclassification of exposure and potentially bias the results. However, as this would result in nondifferential misclassification, it would most likely result in bias towards the null. Moreover, we had insufficient brain tumor cases to examine duration of exogenous hormone use with sufficient power, or to explore analyses with different hormone combinations. Our findings need to be confirmed in other populations. In this study, we observed an elevated risk of meningioma among current users of HRT or OC. In contrast, other reproductive factors were not associated with Cancer Epidemiology, Biomarkers & Prevention Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Reproductive Factors, Hormone Use, and Brain Tumors the risk of meningioma. Furthermore, no relation was observed for reproductive factors and the risk of glioma. Additional studies should carefully examine the relation with current use of exogenous hormones, both HRT and OC, and meningioma risk. Disclosure of Potential Conflicts of Interest No potential conflicts of interest were disclosed. Grant Support The coordination of EPIC is financially supported by the European Commission (DG-SANCO) and the International Agency for Research on Cancer. The national cohorts are supported by Danish Cancer Society in Denmark; Ligue contre le Cancer, Société 3M, Mutuelle Générale de l'Education Nationale, and Institut National de la Santé et de la Recherche Medicale in France; Deutsche Krebshilfe, Deutsches Krebsforschungszentrum, and Federal Ministry of Education and Research in Germany; Ministry of Health and Social Solidarity, Stavros Niarchos Foundation, and Hellenic Health Foundation in Greece; Italian Association for Research on Cancer (AIRC) and National Research Council in Italy; Dutch Ministry of Public Health, Welfare and Sports (VWS), Netherlands Cancer Registry (NKR), LK Research Funds, Dutch Prevention Funds, Dutch ZON (Zorg Onderzoek Nederland), and World Cancer Research Fund (WCRF) in the Netherlands; Statistics Netherlands; Norwegian Cancer Society in Norway; Health Research Fund (FIS), Regional Governments of Andalucía, Asturias, Basque Country, Murcia and Navarra, and ISCIII RETIC (RD06/0020) in Spain; Swedish Cancer Society, Swedish Scientific Council, and the Regional Government of Skåne and Västerbotten in Sweden; Cancer Research UK, Medical Research Council, Stroke Association, British Heart Foundation, Department of Health, Food Standards Agency, and Wellcome Trust in the United Kingdom. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Received 04/27/2010; revised 07/08/2010; accepted 07/09/2010; published online 10/07/2010. References 1. 2. 3. 4. 5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet 2009;41:905–8. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet 2009;41: 899–904. CBTRUS. Statistical Report: Primary Brain Tumors in the United States, 1998–2002. Central Brain Tumor Registry of the United States; 2005. Koper JW, Lamberts SW. Meningiomas, epidermal growth factor and progesterone. Hum Reprod 1994;9 Suppl 1:190–4. Rao G, Giordano SH, Liu J, McCutcheon IE. The association of breast cancer and meningioma in men and women. Neurosurgery 2009;65:483–9. Lee E, Grutsch J, Persky V, Glick R, Mendes J, Davis F. Association of meningioma with reproductive factors. Int J Cancer 2006;119: 1152–7. Wigertz A, Lonn S, Mathiesen T, Ahlbom A, Hall P, Feychting M. Risk of brain tumors associated with exposure to exogenous female sex hormones. Am J Epidemiol 2006;164:629–36. Wigertz A, Lonn S, Hall P, et al. Reproductive factors and risk of meningioma and glioma. Cancer Epidemiol Biomarkers Prev 2008; 17:2663–70. Huang K, Whelan EA, Ruder AM, et al. Reproductive factors and risk of glioma in women. Cancer Epidemiol Biomarkers Prev 2004;13: 1583–8. Hatch EE, Linet MS, Zhang J, et al. Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer 2005;114:797–805. Custer B, Longstreth WT, Jr., Phillips LE, Koepsell TD, Van Belle G. Hormonal exposures and the risk of intracranial meningioma in women: a population-based case-control study. BMC Cancer 2006;6:152. Cantor KP, Lynch CF, Johnson D. Reproductive factors and risk of brain, colon, and other malignancies in Iowa (United States). Cancer Causes Control 1993;4:505–11. Cicuttini FM, Hurley SF, Forbes A, et al. Association of adult glioma with medical conditions, family and reproductive history. Int J Cancer 1997;71:203–7. Hochberg F, Toniolo P, Cole P, Salcman M. Nonoccupational risk indicators of glioblastoma in adults. J Neurooncol 1990;8:55–60. Schlehofer B, Blettner M, Wahrendorf J. Association between brain tumors and menopausal status. J Natl Cancer Inst 1992;84: 1346–9. Felini MJ, Olshan AF, Schroeder JC, et al. Reproductive factors and hormone use and risk of adult gliomas. Cancer Causes Control 2009; 20:87–96. www.aacrjournals.org 17. Lambe M, Coogan P, Baron J. Reproductive factors and the risk of brain tumors: a population-based study in Sweden. Int J Cancer 1997;72:389–93. 18. Silvera SA, Miller AB, Rohan TE. Hormonal and reproductive factors and risk of glioma: a prospective cohort study. Int J Cancer 2006;118:1321–4. 19. Jhawar BS, Fuchs CS, Colditz GA, Stampfer MJ. Sex steroid hormone exposures and risk for meningioma. J Neurosurg 2003;99:848–53. 20. Benson VS, Pirie K, Green J, Casabonne D, Beral V. Lifestyle factors and primary glioma and meningioma tumours in the Million Women Study cohort. Br J Cancer 2008;99:185–90. 21. Blitshteyn S, Crook JE, Jaeckle KA. Is there an association between meningioma and hormone replacement therapy? J Clin Oncol 2008; 26:279–82. 22. Benson VS, Pirie K, Green J, et al. Hormone replacement therapy and incidence of central nervous system tumours in the million women study. Int J Cancer 2010;127:1692–8. 23. Riboli E, Hunt KJ, Slimani N, et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection. Public Health Nutr 2002;5:1113–24. 24. Allen NE, Key TJ, Dossus L, et al. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). Endocr Relat Cancer 2008;15:485–97. 25. Saitoh Y, Oku Y, Izumoto S, Go J. Rapid growth of a meningioma during pregnancy: relationship with estrogen and progesterone receptors-case report. Neurol Med Chir (Tokyo) 1989;29:440–3. 26. Wan WL, Geller JL, Feldon SE, Sadun AA. Visual loss caused by rapidly progressive intracranial meningiomas during pregnancy. Ophthalmology 1990;97:18–21. 27. Bickerstaff ER, Small JM, Guest IA. The relapsing course of certain meningiomas in relation to pregnancy and menstruation. J Neurol Neurosurg Psychiatry 1958;21:89–91. 28. Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med 2007; 357:2411–2. 29. Jay JR, MacLaughlin DT, Riley KR, Martuza RL. Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 1985;62:757–62. 30. Kang SH, Cho HT, Devi S, et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res 2006;66:11991–7. 31. Lis A, Ciesielski MJ, Barone TA, Scott BE, Fenstermaker RA, Plunkett RJ. 2-Methoxyestradiol inhibits proliferation of normal and neoplastic glial cells, and induces cell death, in vitro. Cancer Lett 2004;213:57–65. 32. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide. Lyon, France: IARC Press; 2010. Cancer Epidemiol Biomarkers Prev; 19(10) October 2010 Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research. 2569 Published OnlineFirst August 27, 2010; DOI: 10.1158/1055-9965.EPI-10-0447 Reproductive Factors and Exogenous Hormone Use in Relation to Risk of Glioma and Meningioma in a Large European Cohort Study Dominique S. Michaud, Valentina Gallo, Brigitte Schlehofer, et al. Cancer Epidemiol Biomarkers Prev 2010;19:2562-2569. Published OnlineFirst August 27, 2010. Updated version Cited articles Citing articles E-mail alerts Reprints and Subscriptions Permissions Access the most recent version of this article at: doi:10.1158/1055-9965.EPI-10-0447 This article cites 30 articles, 6 of which you can access for free at: http://cebp.aacrjournals.org/content/19/10/2562.full#ref-list-1 This article has been cited by 4 HighWire-hosted articles. Access the articles at: http://cebp.aacrjournals.org/content/19/10/2562.full#related-urls Sign up to receive free email-alerts related to this article or journal. To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org. To request permission to re-use all or part of this article, use this link http://cebp.aacrjournals.org/content/19/10/2562. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site. Downloaded from cebp.aacrjournals.org on January 12, 2022. © 2010 American Association for Cancer Research.